PMA supplement
P210026 S003: Ki-67 IHC MIB-1 pharmDx (Dako Omnis)
FDA PMA supplement · 30-Day Notice · Agilent Technologies, Inc.
Key facts
| Original PMA | P210026 |
|---|---|
| Supplement number | S003 |
| Supplement type | 30-Day Notice |
| Reason for the supplement | Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | Ki-67 IHC MIB-1 pharmDx (Dako Omnis) |
| Generic name | Immunohistochemistry assay, antibody, Ki-67 |
| Applicant | Agilent Technologies, Inc. |
| Product code | QQT |
| Received date | Aug 14, 2026 |
| Decision date | Sep 11, 2026 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: